Evidence map›Paper›PMID 38233947›Full record

ArticleArthritis research & therapy2024

Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray.

Jing Huang, Honglin Zhu, Sijia Liu, Mengtao Li, Yisha Li, Hui Luo, Xiaoxia Zuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jing HuangDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China.
Honglin ZhuDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China.
Sijia LiuDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China. celialiu@csu.edu.cn.
Mengtao LiDepartment of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Beijing, 100730, China. mengtao.li@cstar.org.cn.
Yisha LiDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China.
Hui LuoDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China.
Xiaoxia ZuoDepartment of Rheumatology, Xiangya Hospital, Central South University, Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Changsha, China.
Central South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-005
6 · The paper itself

Abstract

backgroundPulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of systemic sclerosis (SSc)-related death. In this study, we aimed to identify biomarkers for detecting SSc pulmonary complications that are mild and in the early stages to improve the prognosis.

methodsWe screened for serum biomarkers using a proteomic antibody microarray that simultaneously assessed 1000 proteins. Differentially expressed proteins were further verified using ELISA. Finally, we performed a correlation analysis using clinical data.

resultsWe identified 125 differentially expressed proteins, of which calcitonin, sclerostin (SOST), CD40, and fibronectin were selected for further verification. Serum calcitonin and SOST levels were significantly elevated in all SSc pulmonary complication subgroups, whereas serum calcitonin levels were higher in the SSc with PAH subgroup than in the SSc without PAH and ILD subgroup. Serum SOST levels were possibly associated with the presence of ILD and positively related to the presence of cardiac and gastrointestinal involvement. Serum CD40 and calcitonin levels appeared to be positively related to the presence of renal involvement, and serum calcitonin was also positively related to the presence of gastrointestinal involvement.

conclusionsThis study indicated that serum calcitonin and SOST levels may be promising biomarkers for SSc-related PAH and ILD, respectively. Further research is needed to verify this result and understand the underlying mechanisms.

Indexed as

Hypertension, PulmonaryLung Diseases, InterstitialPulmonary Arterial HypertensionScleroderma, SystemicAntibodiesBiomarkersCalcitoninHumansProteomicsAntibodiesBiomarkersCalcitoninCalcitoninInterstitial lung diseasePulmonary arterial hypertensionSclerostin/SOSTSystemic sclerosis

Identifiers

PMID38233947
PMCPMC10792928
OpenAlexW4390946615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.